123 related articles for article (PubMed ID: 38036271)
1. Effect of Neoadjuvant Concurrent Chemoradiation on Operability and Survival in Locally Advanced Inoperable Breast Cancer.
Iyer P; Krishnamurthy A; Velusamy S; Sundersingh S; Rajaram S; Balasubramanian A; Radhakrishnan V
Int J Radiat Oncol Biol Phys; 2024 May; 119(1):163-171. PubMed ID: 38036271
[TBL] [Abstract][Full Text] [Related]
2. Study of pathological complete response rate with neoadjuvant concurrent chemoradiation with paclitaxel in locally advanced breast cancer.
Iyer P; Radhakrishnan V; Balasubramanian A; Sridevi V; Krishnamurthy A; Dhanushkodi M; Sundersingh S; Ganesarajah S
Indian J Cancer; 2020; 57(4):428-434. PubMed ID: 32675440
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study.
Tampaki EC; Tampakis A; Alifieris CE; Krikelis D; Pazaiti A; Kontos M; Trafalis DT
Clin Drug Investig; 2018 Jul; 38(7):639-648. PubMed ID: 29744672
[TBL] [Abstract][Full Text] [Related]
4. Tumor Biology Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients Presenting with Locally Advanced Breast Cancer.
Gentile LF; Plitas G; Zabor EC; Stempel M; Morrow M; Barrio AV
Ann Surg Oncol; 2017 Dec; 24(13):3896-3902. PubMed ID: 28916978
[TBL] [Abstract][Full Text] [Related]
5. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.
Nahleh ZA; Barlow WE; Hayes DF; Schott AF; Gralow JR; Sikov WM; Perez EA; Chennuru S; Mirshahidi HR; Corso SW; Lew DL; Pusztai L; Livingston RB; Hortobagyi GN
Breast Cancer Res Treat; 2016 Aug; 158(3):485-95. PubMed ID: 27393622
[TBL] [Abstract][Full Text] [Related]
6. A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer.
Symonds L; Jenkins I; Linden HM; Kurland B; Gralow JR; Gadi VVK; Ellis GK; Wu Q; Rodler E; Chalasani P; Chai X; Riedel J; Scca Network Investigators ; Stopeck A; Brown-Glaberman U; Specht JM
Clin Breast Cancer; 2022 Jan; 22(1):32-42. PubMed ID: 34158245
[TBL] [Abstract][Full Text] [Related]
7. Locally advanced breast cancer.
Aebi S; Karlsson P; Wapnir IL
Breast; 2022 Mar; 62 Suppl 1(Suppl 1):S58-S62. PubMed ID: 34930650
[TBL] [Abstract][Full Text] [Related]
8. Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABPĀ Foundation FB-6, a phase II study.
Tan AR; Johannes H; Rastogi P; Jacobs SA; Robidoux A; Flynn PJ; Thirlwell MP; Fehrenbacher L; Stella PJ; Goel R; Julian TB; Provencher L; Bury MJ; Bhatt K; Geyer CE; Swain SM; Mamounas EP; Wolmark N
Breast Cancer Res Treat; 2015 Jan; 149(1):163-9. PubMed ID: 25542269
[TBL] [Abstract][Full Text] [Related]
9. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.
Singh JC; Mamtani A; Barrio A; Morrow M; Sugarman S; Jones LW; Yu AF; Argolo D; Smyth LM; Modi S; Schweber S; Boafo C; Patil S; Norton L; Baselga J; Hudis CA; Dang C
Oncologist; 2017 Feb; 22(2):139-143. PubMed ID: 28167568
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients.
Ezzat AA; Ibrahim EM; Ajarim DS; Rahal MM; Raja MA; Tulbah AM; Al-Malik OA; Al-Shabanah M; Sorbris R
Br J Cancer; 2004 Mar; 90(5):968-74. PubMed ID: 14997191
[TBL] [Abstract][Full Text] [Related]
11. Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer.
Shenkier T; Weir L; Levine M; Olivotto I; Whelan T; Reyno L;
CMAJ; 2004 Mar; 170(6):983-94. PubMed ID: 15023926
[TBL] [Abstract][Full Text] [Related]
12. Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer.
Cho JH; Park JM; Park HS; Park S; Kim SI; Park BW
J Surg Oncol; 2013 Dec; 108(8):531-6. PubMed ID: 24115142
[TBL] [Abstract][Full Text] [Related]
13. Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab.
Shinde AM; Zhai J; Yu KW; Frankel P; Yim JH; Luu T; Kruper L; Vito C; Shaw S; Vora NL; Kirschenbaum M; Somlo G
Breast; 2015 Feb; 24(1):18-23. PubMed ID: 25467313
[TBL] [Abstract][Full Text] [Related]
14. Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer.
Al-Tweigeri TA; Ajarim DS; Alsayed AA; Rahal MM; Alshabanah MO; Tulbah AM; Al-Malik OA; Fatani DM; El-Husseiny GA; Elkum NB; Ezzat AA
Med Oncol; 2010 Sep; 27(3):571-7. PubMed ID: 19526202
[TBL] [Abstract][Full Text] [Related]
15. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
16. Concurrent Neoadjuvant Chemotherapy and Radiation Therapy in Locally Advanced Breast Cancer.
Brackstone M; Palma D; Tuck AB; Scott L; Potvin K; Vandenberg T; Perera F; D'Souza D; Taves D; Kornecki A; Muscedere G; Chambers AF
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):769-776. PubMed ID: 28870785
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer.
Cooper BW; Radivoyevitch T; Overmoyer BA; Shenk RR; Pham HT; Samuels JR; Parry MP; Silverman P
Breast Cancer Res Treat; 2006 Jun; 97(3):311-8. PubMed ID: 16344915
[TBL] [Abstract][Full Text] [Related]
19. Combined neoadjuvant chemotherapy with bevacizumab improves pathologic complete response in patients with hormone receptor negative operable or locally advanced breast cancer.
Makhoul I; Klimberg VS; Korourian S; Henry-Tillman RS; Siegel ER; Westbrook KC; Hutchins LF
Am J Clin Oncol; 2015 Feb; 38(1):74-9. PubMed ID: 23563210
[TBL] [Abstract][Full Text] [Related]
20. Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9.
Abraham J; Robidoux A; Tan AR; Limentani S; Sturtz K; Shalaby I; Alcorn H; Buyse ME; Wolmark N; Jacobs SA
Breast Cancer Res Treat; 2015 Jul; 152(2):399-405. PubMed ID: 26126970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]